In January 2024, the first patients in Australia received treatment with psychedelic-assisted therapy as part of the Therapeutic Goods Administration’s (TGA) Authorised Prescriber (AP) program with medicines and training supplied through Mind Medicine Australia.
This marks the first time patients have received these treatments outside of research in a legal, regulated clinical setting with scheduled psychedelic medicines in over 50 years.
This comes after the TGA’s landmark decision on February 3 2023 to reschedule MDMA and psilocybin in Australia in response to applications lodged by Mind Medicine Australia. This decision reclassified MDMA and Psilocybin from Schedule 9 (Poisons) to Schedule 8 (Controlled Substances) on a restricted basis. From July 1 2023 psychiatrists have been able to apply to become Authorised Prescribers (AP) for psilocybin and MDMA. Psychiatrists with AP status can prescribe these substances as part of therapy for patients with treatment-resistant depression (psilocybin) and treatment-resistant post-traumatic stress disorder (MDMA).
Treatments are supervised by experienced clinicians and therapists who have been trained through Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies and other authorised training programs.
Medicines are supplied through our partnership with Optimi Health in Canada.
Please contact hello@mindmedicineaustralia.org for more information.